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Abstract: The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC)
susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified
and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC
(mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment
for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a
fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin
alterations in the context of GC to characterize subtypes of patients that could better benefit from
targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms
(rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed.
Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will
benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding
the HER2 and the E-cadherin interactions in vivo and in response to treatments.
Keywords: E-cadherin; CDH1; HER2; metastatic gastric cancer; rs16260; rs1801552
1. Introduction
Gastric cancer (GC) is a serious health problem worldwide. This year 28,000 new cases, with
approximately 10,960 related deaths, are expected in the United States [1]. Even though surgery is
the primary treatment option for early stage GC, diagnosis is often late in Western countries. This is
probably due to the lack of proper screening programs and a lack of symptoms for a long time. About
35% of patients present with “de novo” metastatic GC (mGC) and approximately 70% that underwent
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surgery for the primary tumor will have disease recurrence or develop distant metastases, with a
median survival of about one year, despite palliative chemotherapy [2–4].
In selected small tumors (i.e., stage Tis or T1) endoscopic resection may be performed, mainly
in experienced centers. However, complete tumor resection with adequate margins and lymph
node dissection remains the only potentially curative therapy for patients with non-metastatic GC.
Furthermore, perioperative chemotherapy can improve survival outcomes for patients with operable
disease [5].
In metastatic or recurrent disease, chemotherapy is the standard treatment, although it is not
curative. However, despite the introduction in clinical practice of new drugs and chemotherapeutic
schedules, only little progress has been made in recent years. The most important advance came
from the international (24 countries) phase 3 randomized “ToGA” study (NCT01041404) [6]. In this
trial, the addition of the trastuzumab, a monoclonal antibody, to the chemotherapy with cisplatin
and capecitabine was compared to the same chemotherapy combination alone, in a population of
HER2-positive metastatic gastric or gastro-esophageal junction cancers. The HER2 is a transmembrane
protein with tyrosine kinase activity implicated by its interaction with epidermal growth factor (EGF)
family in cell growth and differentiation (Figure 1). In the ToGA study the median overall survival
(OS) was found to be higher in patients who received trastuzumab plus chemotherapy compared
with those who received the only chemotherapy (13.8 vs. 11.1 months). Immunohistochemical (IHC)
scoring evaluates both the HER2 membranous staining (absent, weak or detected in only one part
of the membrane, moderate/weak complete or basolateral membranous staining and strong) and
the percentage of the tumor cells staining (<10% or ≥ 10% of cells). A greater survival benefit was
detected in patients whose tumors were IHC-positive (score 3+) or IHC-equivocal (score 2+), but in situ
hybridization-positive (16 vs. 11.8 months; hazard ratio (HR) = 0.65). In addition, it was seen that the
addition of the trastuzumab to chemotherapy did not compromise patient quality of life. Unfortunately,
in a substantial proportion of mGC patient who progress after initial response to chemotherapy the
death occurs in a few months [4]. Furthermore, the prognostic significance of the HER2 expression in
GC remains to be elucidated.
Breakthroughs in the GC biology are currently changing the landscape of GC. More specifically,
the understanding of molecular mechanisms underlying the different pathological features has led to
new GC classifications [7,8]. Originally GC was categorized according to anatomical presentation [9,10],
and to histological classes (WHO classification and Lauren classification) [11,12]. More recently, the
characterization of GC includes the HER2 status and the HER-positive disease is reported in about
18% (range 4.4% to 53.4%) of patients [13].
In 2014, the Cancer Genome Atlas (TGCA) project [14] subdivided GC according to different
molecular biology tests in four subgroups: EBV-positive (about 8% of all GC), Microsatellite
Instable (MSI, about 22%), Chromosomal Instable (CIN, about 50%), and Genomically Stable
(GS, about 20%) cancers. Additionally, in 2015 the Asian Cancer Research Group (ACRG) [15]
proposed an alternative molecular classification due to the different biological characteristics of
Asian patients. This classification divided GC in four subgroups represented by: Microsatellite
Stable/epithelial-to-mesenchymal transition (MSS/EMT), Microsatellite Stable TP53-positive
(MSS/TP53+, somehow overlapping with EBV type of TCGA classification), Microsatellite Stable
TP53-negative (MSS/TP53−, similar to CIN by TCGA), and Microsatellite Instable (MSI).
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Figure 1. Schematic diagram of E-cadherin-HER2 interaction. The E-cadherin present three different 
domains: the conserved cytoplasmic domain, a transmembrane domain, and an extracellular domain. 
The E-cadherin cytoplasmic tail presents two regions: the catenin-binding domain and the 
juxtamembrane domain. β-catenin binds to the E-cadherin domain and this complex via α-catenin 
connects and regulates E-cad interaction with the actin cytoskeleton. p120-catenin binds the CDH1 
juxtamembrane domain and stabilizes E-cad expression at the cell surface. (A) Activation of the HER2 
by inducing the phosphorylation of β-catenin directs the dissociation of β-catenin from the E-cad 
complex, thus leading to a decrease of E-cad-mediated cell adhesion, facilitate epithelial-
mesenchymal transition (EMT), and the translocation of β-catenin to the nucleus where it acts as a 
transcriptional regulator of genes involved in cell growth and the EMT process; (B) HER2 activation 
increases metalloproteinase (MP) activity, which leads to an increased production of soluble E-
cadherin (sE-cad) through the cleavage of E-cad. Metalloproteinase also cleaves HER2 into a 
cytoplasmic tail domain, p95HER2, and a shaded soluble HER2 fragment. The p95HER2 fragment 
maintains the phosphokinase activity, thus favoring the dissociation of the β-catenin/E-cad complex 
leading to GC progression and metastasis. The production of the sE-cad causes a reduction in cell 
adhesion and, by its diffusion into the microenvironment, acts as a paracrine/autocrine signaling 
molecule that regulates numerous signaling pathways implicated in tumor progression, including a 
key role in the HER2 interaction/activation and phosphorylation of β-catenin.  
Figure 1. Schematic diagram of E-cadherin-HER2 interaction. The E-cadherin present three different
domains: the conserved cytoplasmic domain, a transmembrane domain, and an extracellular
domain. The E-cadherin cytoplasmic tail presents two regions: the catenin-binding domain and
the juxtamembrane domain. β-catenin binds to the E-cadherin domain and this complex via α-catenin
connects and regulates E-cad interaction with the actin cytoskeleton. p120-catenin binds the CDH1
juxtamembrane domain and stabilizes E-cad expression at the cell surface. (A) Activation of the HER2
by inducing the phosphorylation of β-catenin directs the dissociation of β-catenin from the E-cad
complex, thus leading to a decrease of E-cad-mediated cell adhesion, facilitate epithelial-mesenchymal
transition (EMT), and the translocation of β-catenin to the nucleus where it acts as a transcriptional
regulator of genes involved in cell growth and the EMT process; (B) HER2 activation increases
metalloproteinase (MP) activity, which leads to an increased production of soluble E-cadherin (sE-cad)
through the cleavage of E-cad. Metalloproteinase also cleaves HER2 into a cytoplasmic tail domain,
p95HER2, and a shaded soluble HER2 fragment. The p95HER2 fragment maintains the phosphokinase
activity, thus favoring the dissociation of the β-catenin/E-cad complex leading to GC progression and
metastasis. The production of the sE-cad causes a reduction in cell adhesion and, by its diffusion into the
microenvironment, acts as a paracrine/autocrine signaling molecule that regulates numerous signaling
pathways implicated in tumor progression, including a key role in the HER2 interaction/activation
and phosphorylation of β-catenin.
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In the present study, our attention is focused on tumors with CDH1 mutation, which could be
included in the GS subtype of TCGA classification, mostly represented by GC of diffused histotype
widely distributed to all the anatomical sites of the stomach and tending to a metastatic process linked
to EMT [14]. CDH1 encodes the E-cadherin (E-cad), a transmembrane glycoprotein especially abundant
in epithelial tissues that mediate calcium-dependent adhesion between epithelial cells. Several CDH1
mutations with a reduced activity/expression of the E-cad [16], as well as the HER2 overexpression [17],
have been associated with shorter GC patient survival. More recent evidence points to β-catenin as
a common link between the HER2 overexpression and the E-cad repression in influencing EMT, the
metastatic process, and outcome [18].
A deep understanding of molecular characterization of patients with mGC focusing on both the
HER2-positive and the CDH1 polymorphisms could provide the scientific background to develop
modern clinical trial protocols in order to maximize the benefit of novel biological agents in a proper
patient population [7]. The present study was designed to characterize CDH1 in mGC subtypes
according to the HER2-expression and to evaluate the association between the CDH1 and the prognosis.
2. Results
2.1. Patient Characteristics
Fifty-nine consecutive patients with mGC were enrolled in this study; patients meeting the criteria
for hereditary diffuse GC have been excluded. In total, 44 patients were males and 15 were females,
and the mean age at diagnosis was 60 years (range, 40–76 years). Twelve cases (20.3%; (N = 10 males,
median age 56.5 years) were classified at diagnosis as HER2-positive by an IHC score of 2+/neu
amplification or by an IHC score of 3. All mGC patients received the same chemotherapeutic regimen
with the addition of trastuzumab in mGC HER2-positive tumors (mGC-HER2).
At a median follow-up time of two years, a trend for a better OS was showed in the mGC-HER2
positive group of patients although due to the limited number of cases the difference did not reach
a statistical significance (468 days, standard deviation (SD) 389 vs. 584 days, SD 336; p = 0.20)
(Figure 2). These data are in accord with previous studies reported in the literature, which used
targeted treatment [6,19].
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Figure 2. Cox regression for overall survival (OS) analysis for the mGC patient subgroup based on 
the HER2-expression. 
2.2. CDH1 Mutations  
A summary of CDH1 mutations found in the promoter/5′UTR region and in all 16 exons and their 
surrounding sequences, are reported in Table 1, stratified on the basis of the HER2 status. Mutations 
resulted in: (i) missense variant in three cases (mGC-HER2 P296, mGC P310, P623); (ii) a frameshift 
variant in one case resulting in a truncating protein (mGC-HER2 P586) [20]; (iii) synonymous mutations 
in seven cases, including a new mutation (GeneBank accession number: KT820428.1) (mGC-HER2 P586, 
mGC P310, P295, P311, P476, P368, P490); and (iv) eight in the non-coding region (i.e., 
promoter/5′UTR/surrounding regions) (mGC-HER2 P586, mGC P377, P304, P294, P376, P479, P368, 
P490). Six among these mutations resulted in a polymorphic site (≥5% allele frequency) (Table 1) 
(rs5030625 c.-472delA, rs16260 c.-285C>A, rs3743674 c.48+6C>T, rs2276330 c.1937-13T>C, rs1801552 
c.2076T>C and rs33964119 c.2253C>T). Allele and genotype frequencies of the six polymorphic variants 
are reported in Table 2 stratified based on the mGC-HER2 expression. A significant association was 
found between the rs16260 c.-285 A-allele and HER2-positive mGC (p = 0.0009). 
Figure 2. Cox regression for overall survival (OS) analysis for the mGC patient subgroup based on the
HER2-expression.
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2.2. CDH1 Mutations
A summary of CDH1 mutations found in the promoter/5′UTR region and in all 16 exons and
their surrounding sequences, are reported in Table 1, stratified on the basis of the HER2 status.
Mutations resulted in: (i) missense variant in three cases (mGC-HER2 P296, mGC P310, P623); (ii) a
frameshift variant in one case resulting in a truncating protein (mGC-HER2 P586) [20]; (iii) synonymous
mutations in seven cases, including a new mutation (GeneBank accession number: KT820428.1)
(mGC-HER2 P586, mGC P310, P295, P311, P476, P368, P490); and (iv) eight in the non-coding region
(i.e., promoter/5′UTR/surrounding regions) (mGC-HER2 P586, mGC P377, P304, P294, P376, P479,
P368, P490). Six among these mutations resulted in a polymorphic site (≥5% allele frequency) (Table 1)
(rs5030625 c.-472delA, rs16260 c.-285C>A, rs3743674 c.48+6C>T, rs2276330 c.1937-13T>C, rs1801552
c.2076T>C and rs33964119 c.2253C>T). Allele and genotype frequencies of the six polymorphic variants
are reported in Table 2 stratified based on the mGC-HER2 expression. A significant association was
found between the rs16260 c.-285 A-allele and HER2-positive mGC (p = 0.0009).
2.3. Association between CDH1 P7-Haplotype and mGC-HER2
We investigated the association between mGC stratified by HER2 expression and the CDH1
haplotype resulting from the six polymorphic sites dispersed over the entire CDH1 gene. A total of
11 different CDH1 haplotypes were identified and their frequencies reported in Table 3. Haplotype
P7 was exclusively present in six mGC-HER2 patients, one of them showing a P7 haplotype in
homozygous cases (Table 4). Linkage disequilibrium (LD) analysis in mGC patients showed a tight
association between rs16260 and rs1801552 (D′ = 1.0000, R2 = 0.1731, χ2 = 16.2759, p = 0.0001), which
was not present in mGC-HER2 (D′ = 0.3555, R2 = 0.0721, χ2 = 1.7311, p = 0.1883). The contemporary
presence of the rs16260-A allele and rs1801552-T-allele, both included in the P7 haplotype, was strictly
associated with mGC-HER2 disease (Table 3).
2.4. Association between the CDH1 P7 Haplotype and the Survival of mGC-HER2 Patients
The relationship between the P7 haplotype and OS was statistically analyzed by using Cox
regression curves. The P5, P6, and P8–P11 haplotypes with less than two cases in mGC-HER2 (Table 3)
were combined in a unique group, and designed them as haplotype “matched”. Figure 3A shows the
OS of all GC cases (independent of the HER2-expression) stratified on haplotype-based approaches.
The haplotype P7 was associated with better outcome (median OS: 1037 days) compared to the other
haplotypes (median OS: 312 to 448 days). Notably, a significantly worse prognosis was observed with
the “matched” haplotype (median OS: 312 days; HR 2.79, 95% CI 1.032–7.548) and the haplotype
P1 (median OS: 419 days; HR 2.54, 95% CI 1.049–6.169). The haplotype P7 was present only in the
mGC-HER2 group where it distinguished patients with better survival compared to those with the
“matched” haplotype and haplotype P1 (HR 4.33, 95% CI 1.033–7.548; HR 2.58, 95% CI 0.328–20.275,
respectively). The “matched” haplotype and haplotype P1 were also associated with poorer prognosis
in mGC group when compared to haplotype P3 (HR 1.412, 95% CI 0.717–2.779). Figure 3B indicates
the OS distribution according to the restricted GC haplotype (i.e., rs16260 and rs1801552), specifically
associated with the mGC-HER2 patients as reported above. Data confirmed the better outcome was
associated with the restricted AT haplotype (median OS: 1037 days, 95% CI 371–1037) which, in our
series, is supported by the observation of a statistically significant difference in the OS compared to the
CC haplotype (median OS: 420 days, 95% CI 312–500; HR 2.374, 95% CI 1.077–5.229).
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Table 1. CDH1 germline mutations found in mGC according to the HER2-expression.
CDH1 Region
Gene
Reference
Polymorphism cDNA Change
Amino Acid
Change
Type of Variant
Genotype
mGC-HER2 (n) mGC (n)
Promoter rs5030625 c.-472delA Polymorphic variant G/A (1) G/A (10)
Promoter rs16260 c.-285C>A Polymorphic variant A/A (4) A/C (6) A/A (3) A/C (16)
Promoter rs34149581 c.-276T>C T/C (1)
5′UTR rs34033771 c.-71C>G C/G (1)
IV1 rs3743674 c.48+6C>T Polymorphic variant C/C (1) T/C (9) C/C (1)
EXON3 rs1801023 c.345G>A p.Thr115= Synonymous variant G/A (1)
IV4 rs33963999 c.531+10G>C G/C (2)
IV5 rs189969617 c.688-14C>T C/T (1)
EXON7 rs142822590 c.892G>A p.Ala298Thr Missense variant G/A (1)
EXON11 SCV000588228.1 c.1612delG p.Asp538Thrfs*19 Frameshift mutation delG (1)
EXON12 rs35187787 c.1774G>A p.Ala592Thr Missense variant G/A (1)
EXON12 rs33969373 c.1896C>T p.HIS632= Synonymous variant C/T (2)
IV12 rs2276330 c.1937-13T>C Polymorphic variant C/T (2) C/T (10)
EXON13 rs1801552 c.2076T>C p.Ala692= Polymorphicsynonymous variant C/T (5) T/T (3) C/T (24) T/T (5)
IV13 rs35686369 c.2164+15_2164+16insA insA (1) insA (2)
EXON14 rs879026401 c.2232A>G p.Pro744= Synonymous variant A/G (1)
EXON14 rs33964119 c.2253C>T p.Asn751= Synonymous variant C/T (1) C/T (2)
EXON15 rs587782549 c.2204G>A p.Arg796Gln Missense variant G/A (1)
Abbreviations: HER2, human epidermal growth factor receptor 2; mGC, metastatic gastric cancer. Filled boxes correspond to the polymorphic variants.
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Table 2. Allele and genotype frequencies of CDH1 polymorphic sites in patients with mGC according
to the HER2-expression.
Reference
Polymorphism Allele/Genotype mGC-HER2 Frequency mGC Frequency p OR (95% CI)
rs5030625
Allele
G 23 0.96 84 0.89
0.33 2.738 (0.33–22.51)A 1 0.04 10 0.11
Genotype
G/G 11 0.92 37 0.79
G/A 1 0.08 10 0.21
A/A 0 0.00 0 0.00
Dominant model GG/AA+AG 11/1 0.92/0.08 37/10 0.79/0.21 0.30 2.973 (0.34–25.86)
Recessive model AA/AG+GG 0/12 0.00/1.00 0/47 0.00/1.00 nv
rs16260
Allele
A 14 0.58 22 0.23 ≤0.001 4.582 (1.79–11.75)C 10 0.42 72 0.77
Genotype
A/A 4 0.33 3 0.06
A/C 6 0.50 16 0.34
C/C 2 0.17 28 0.60
Recessive model CC/AA+AC 2/10 0.17/0.83 28/19 0.60/0.40 ≤0.01 7.368 (1.45–37.46)
Dominant model AA/AC+CC 4/8 0.33/0.67 3/44 0.06/0.94 0.01 7.333 (1.37–39.18)
rs3743674
Allele
T 22 0.92 83 0.88
0.64 1.457 (0.30–7.07)C 2 0.08 11 0.12
Genotype
T/T 11 0.92 37 0.79
T/C 0 0.00 9 0.19
C/C 1 0.08 1 0.02
Recessive model CC/CT+TT 1/11 0.08/0.92 1/46 0.02/0.98 0.29 4.182 (0.24–72.21)
Dominant model TT/CC+CT 11/1 0.92/0.08 37/10 0.79/0.21 0.30 2.973 (0.34–25.86)
rs2276330
Allele
T 22 0.92 84 0.90
0.74 1.309 (0.27–6.42)C 2 0.08 10 0.11
Genotype
T/T 10 0.83 37 0.79
T/C 2 0.17 10 0.21
C/C 0 0.00 0 0.00
Dominant model TT/CT+CC 10/2 0.83/0.17 37/10 0.79/0.21 0.72 1.351 (0.25–7.19)
Recessive model CC/TT+CT 0/12 0.00/1.00 0/47 0.00/1.00 nv
rs1801552
Allele
C 13 0.54 60 0.64
0.39 0.670 (0.27–1.66)T 11 0.46 34 0.36
C/C 4 0.33 18 0.38
Genotype T/C 5 0.42 24 0.51
T/T 3 0.25 5 0.11
Recessive model TT/CC+CT 3/9 0.25/0.75 5/42 0.11/0.89 0.19 2.800 (0.56–13.90)
Dominant model CC/CT+TT 4/8 0.33/0.67 18/29 0.38/0.62 0.75 1.241 (0.33–4.72)
rs33964119
C 23 0.96 92 0.98 0.58 0.500 (0.04–5.76)
Allele T 1 0.04 2 0.02
C/C 11 0.92 45 0.96
Genotype T/C 1 0.08 2 0.04
T/T 0 0.00 0 0.00
Recessive model CC/CT+TT 11/1 0.92/0.08 45/2 0.96/0.04 0.57 2.045 (0.17–24.66)
Dominant model TT/CC+CT 0/12 0.00/1.00 0/47 0.00/1.00 nv
Abbreviations: HER2, the human epidermal growth factor receptor 2; OR, odds ratio; is the relative measure
of the number of an allele or a genotype in the mGC-HER2 group relative to the comparison of the number of
allele/genotype in the mGC, by considering as the reference the most frequent allele in the mGC-HER2. If the
OR is >1 the allele or genotype having the greatest frequency in the mGC-HER2 is higher than that found in the
mGC group. 95% CI (confidence interval) is the probability that the confidence interval contains the true odds ratio.
Statistically significant p values are reported in bold type.
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Table 3. Haplotype analysis in patients with mGC according to HER2 expression.
Haplotype mGC (N 94) Frequency mGC-HER2 (N 24) Frequency p OR (95% CI)
rs5030625 rs16260 rs3743674 rs2276330 rs1801552 rs33964119
P1 G C T T C C 19 0.20 2 0.08 0.24 0.359 (0.08–1.67)
P2 G A T T C C 22 0.23 6 0.25 1.00 1.091 (0.39–3.09)
P3 G C T T T C 31 0.33 4 0.17 0.14 0.406 (0.13–1.29)
P4 G C T C C C 9 0.09 2 0.08 1.00 0.859 (0.17–4.26)
P5 A C C T C C 7 0.07 1 0.04 0.69 0.540 (0.06–4.61)
P6 A C C C C C 1 0.01 0 0.00 1.00
P7 G A T T T C 0 0.00 7 0.29 ≤0.001
P8 G C C T T C 1 0.01 0 0.00 1.00
P9 A C C T T C 2 0.02 0 0.00 1.00
P10 G C T T C T 2 0.02 1 0.04 0.50 2.00 (0.17–23.03)
P11 G A C T C C 0 0.00 1 0.04 0.20
Abbreviations: HER2, human epidermal growth factor receptor 2; mGC, metastatic gastric cancer; OR, odds ratio; is the relative measure of the number of the mGC haplotype relative to
the comparison of the number of the same haplotype in the mGC-HER2, by considering as the reference the most frequent haplotype in the mGC. If the OR is >1 the haplotype having the
most frequency in the mGC is higher than that found in the mGC-HER2 group. 95% CI (confidence interval) is the probability that the confidence interval contains the true odds ratio.
Statistically significant p values are highlighted and reported in bold type.
Table 4. CDH1 haplotype plus germline mutation found in patients with HER2-mGC.
Patient Identifier Haplotype
CDH1 Germline Mutation
EXON11
c.1612delG
EXON12
c.1774G>A
IV13
c.2164+15_2164+16insA
EXON14
c.2253C>T
P287 P5–P11
P291 P2–P7
P292 P4–P7
P296 P2–P7
P297 P3–P7
P301 P2–P3
P303 P2–P4
P380 P1–P2
P391 P2–P7
P486 P7–P7
P582 P3–P3
P586 P1–P10
mGC, metastatic gastric cancer. Filled boxes indicate the presence of the CDH1 germline mutations, open boxes indicate their absence.
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according to coupled rs16260 and rs1801552 polymorphisms. * indicates a significant difference
compared to the P7 haplotype (panel A) and coupled AT polymorphism (panel B).
3. Discussion
Targeted HER2 therapy for mGC works differently due to the heterogeneity of the tumor. Positivity
for the HER2 status (by IHC or by fluorescence in situ hybridization) is a prerequisite for the HER2
targeted therapy, but it is not sufficient to predict the treatment response. In the present study,
we found an association between specific CDH1 polymorphisms with a subset of HER2-positive
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mGC that, in turn, are associated with distinct prognosis behavior (Figure 3A). The association
between the haplotype P7 with the better OS is not due to the presence of additional mutations to
the P7-related CDH1 mutations since, among the HER2 patients carrying haplotype P7, only one
had an additional non-polymorphic CDH1 mutation (i.e., pt P296 with a missense variant); of note,
this patient experienced a poor prognosis (median OS: 164 days). Notably, analysis of LD in mGC
showed a specific association with two polymorphisms (i.e., CDH1 rs16260 and rs1801552) that were
not found in the HER2-positive mGC. In fact, these polymorphisms showed minor allele frequency
(MAF) variants in mGC-HER2: rs16260-A and rs1801552-T alleles. By using these two polymorphisms
(i.e., rs16260/rs1801552) Cox regression analysis was simplified from 11 to four haplotypes and
confirmed the association of haplotype P7, including the rs16260-A and the rs1801552-T alleles, with
the mGC-HER2 subtype with the best OS (Figure 3B). Functionally, the rs16260-A polymorphism
located in the CDH1 promoter region had been associated with an alteration in the CDH1 transcriptional
efficiency. In vitro testing using luciferase reporter gene revealed that the rs16260-A allele decreased
CDH1 transcriptional activity by 68% compared to the C-allele. However, the effect of rs16260-A variant
on CDH1 expression in vivo is still unknown [21] and a significant decrease of CDH1 production in
the peripheral blood cells of mutation carrier patients compared to that produced in the control-cohort
was not found [22]. Additionally, the potential contribution of rs16260-A allele to GC risk remains
controversial [23,24], while the potential prognostic value of this variant in breast cancer and in
metastatic colon cancer did not reach statistical significance [25,26].
With regard to the second polymorphism, the rs1801552-T, a protective association between this
variant in homozygous and non-syndromic cleft lip has been reported [27]. Recent studies indicated
that patients with cleft lip had a higher incidence of tumors than the general population [28,29] and,
moreover, family members with pathogenetic CDH1 mutation showed a higher incidence of cleft
lip/palate than the general population (6–7% versus about 0.1%) [28,30,31]. In addition, a previous
study by using rs1801552 heterozygous individuals with GC compared to controls demonstrated a
CDH1 allelic expression imbalance in hereditary GC family members with an increase of the ratio of the
CDH1 RNA rs1801552 T-allele/C-allele that was not found in cancer-free individuals [32]. Results had
suggested, for some unknown reason, the reduction of CDH1 C-allele-specific expression in patients at
risk for GC.
In our series we found relationship between the CDH1 variants and patient survival in the setting
of mGC, particularly in the HER2-positive disease. Previous studies supported a functional interaction
between the HER2 and the E-cad. Briefly, the β-catenin binds the C-terminal cytoplasmic domain
of the E-cad and this complex via the α-catenin connects and regulates the E-cad interaction with
the actin cytoskeleton, while association of the p120-catenin with the juxtamembrane domain of
the E-cad stabilizes the E-cad expression at the cell surface (Figure 1). Activation of the HER2 by
inducing the phosphorylation of the β-catenin directs the dissociation of β-catenin from the E-cad
complex, thus leading to a decrease of the E-cad-mediated cell adhesion facilitating tumor cells
invasion and migration. In addition, the dissociation of the β-catenin from the E-cad complex causes
the translocation of the β-catenin to the nucleus which drives the transcription of various target genes
associated with cell survival, proliferation and metastasis. E-cad can also be solubilized (sE-cad)
by membrane E-cad cleavage and be released into the extracellular environment [33] (Figure 1).
The production of sE-cad not only undermines adherence junctions, but, by its diffusion into the
micro environment, it regulates numerous signals implicated in tumor progression, including a key
role in HER2 interaction/activation and phosphorylation of the β-catenin [18]. Furthermore, HER2
activation was known to increase metalloproteinase activity and, thus, it further leads to high increased
production of the sE-cad by the cleavage of the E-cad. Through the specific cleavage of its cytoplasmic
tail domain into the p95HER2 fragment, it maintains the phosphokinase activity of the HER2 favoring
the dissociation of the β-catenin/E-cad complex that, overall, both promote GC progression and
metastasis (Figure 1).
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Overall, these findings support a possible functional role of the E-cad in response to the
anti-HER2 treatment in mGC-HER2 subtype. However, the role of the CDH1 mutations in this context
requires elucidation through further studies. Interestingly, in human transfected breast epithelial cell
lines over-expressing the HER2 receptor resulted in inhibition of E-cad expression [34]. Lapatinib
resistance in HER2-positive breast cancer cells was also associated with a EMT and the EMT-related
down-regulation of E-cad [35]. Moreover, treatment with the HER2-specific tyrosine kinase inhibitors
(AG285 and HER2 siRNA) was found to produce a down-regulation of the E-cad in ovarian cancer
cells [36]. Overall, these studies demonstrate the important connection between HER2 and E-cad in
human cancers.
The determination of the HER2 status in patients with advanced GC is crucial in order to select
patients who may benefit from the new anti-HER2 agents; the results of this study, if confirmed in a
prospective larger series, could improve the understanding of molecular interactions between HER2
and E-cad and define their role as predictive factors for targeted therapy.
4. Materials and Methods
4.1. Study Population
For the present study, between 2011 and 2017 we enrolled 59 consecutive patients with
confirmatory of metastatic GC. Forty-four were males and 15 were females, and the mean age
at diagnosis was 60 years (range, 40–76 years). Patients were grouped according to confirmed
HER2-status at diagnosis. Patients agreed to participate to the study and provided informed consent
(CRO-2011-2012 Code EUDRACT: 2011-001720-37).
4.2. Genotyping Analysis
Genomic DNA was extracted from each subject’s peripheral blood lymphocytes using an EZ1
DNA blood kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions.
Screening for mutations of CDH1 exons and neighboring intronic sequences was performed
using the polymerase chain reaction (PCR) with previously-described primers and the reaction
conditions [37]. In short, 15 individual PCR reactions were performed on each sample for a full
mutational screen of all 15 exons and splice junctions of the CDH1 gene. Amplified PCR products were
sequenced on an Applied Biosystems 3130 automated sequencer (Applied Biosystems, Foster City, CA,
USA) using the Big Dye v3.1 Terminator Cycle Sequencing Kit (Life Technologies, Monza, Italy) and
sequence data were aligned and analyzed using CodonCode Aligner software.
The promoter, 5′UTR and the exon 1 polymorphisms were genotyped by PCR method.
A 581-bp fragment containing this region was amplified with the following primers: the
forward CDH1FPRO 5′-TCCCAGGTCTTAGTGAGCCA-3′ and the reverse CDH1Exon1REV
5′-TGACGACGGGAGAGGAAG-3′. The amplification was performed in a programmable thermal
cycler as follows: touchdown (hold (94 ◦C 4 min) eight cycles (94 ◦C 45 s; 58 ◦C 50 s; 72 ◦C 1 min;
reducing the annealing temperature by 1 ◦C each cycle)), three cycles (94 ◦C 45 s; 53 ◦C 50 s; 72 ◦C
1 min), and a final cycle of 72 ◦C for 10 min. After amplification the PCR product was sequenced using
the primer CDH1FPRO.
We screened each of the above samples for the c.-472delA CDH1 polymorphism using a new
PCR method in place of current genotyping analysis by the PCR-RFLP method. DNA fragments
containing the promoter region of interest were amplified with two distinct PCR reaction using the
following primers: 1◦ reaction (forward, CDH1G347proFor 5′-CAGCTTGGGTGAAAGAGTGAGC-3′;
reverse ECad347Rev 5′-GGCCACAGCCAATCAGCA-3′); 2◦ reaction (forward, CDH1GA347proFor
5′-CAGCTTGGGTGAAAGAGTGAGA-3′; reverse ECad347Rev 5′-GGCCACAGCCAATCAGCA-3′).
The PCR conditions were set as follows: initial denaturation at 94 ◦C for 4 min; 10 cycles at 94 ◦C
for 30 s, 65 ◦C for 1 min, 20 cycles at 94 ◦C for 30 s, 62 ◦C for 30 s and 72 ◦C for 1 min; and a final
extension at 72 ◦C for 8 min, in a Veriti Thermal Cycler (Life Technologies). PCR products were
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analyzed on a 2.5% agarose gel stained with ethidium bromide and photographed under UV light.
G/G homozygous cases were represented by DNA bands in the 1◦ reaction, GA/GA homozygous
cases were represented by DNA bands in the 2◦ reaction. G/GA heterozygous cases display a
combination of both bands. To validate this new PCR method the promoter region of same samples
was amplified using the following primers: forward, 5′-GCCCCGACTTGTCTCTCTAC-3′; reverse,
5′-GGCCACAGCCAATCAGCA-3′ and PCR products were sequenced.
4.3. Immunohistochemistry
A formalin-fixed, paraffin-embedded tumor block was cut into 4-µm-thick sections for H and
E and immunostaining. Immunohistochemistry was performed by using the rabbit monoclonal
antibodies against HER 2 (clone 4B5, Ventana Medical System, Tucson, AZ, USA).
4.4. Statistical Analysis
The frequencies of allele and genotype were compared between mGC-HER2 and mGC patients
by means of chi-squared test (VassarStats, http://faculty.vassar.edu/lowry/VassarStats.html).
The haplotype frequencies were analyzed with the SNPator [38] and Arlequin software [39].
Survival analysis was performed at the time of the first treatment by using Cox regression analysis.
5. Conclusions
In conclusion, the evaluation of a restricted CDH1 haplotype in mGC could help to select the
patients that gain greater benefit from the anti-HER2 treatments. Furthermore, since a high level of the
sE-cadherin may modulate sensitivity to RTK inhibitors, the evaluation of its serum concentration in
different phases of treatment could have a role in monitoring the therapeutic response overtime.
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